<div>
  <ul>
    <li>
      <p>
        AI precision biotechnology company Neuron23 has partnered with molecular diagnostics incumbent QIAGEN to develop a next-generation companion diagnostic (CDx) for Parkinson&rsquo;s disease targeting Neurons23's LRRK2 inhibitor.&nbsp;
      </p>
    </li>
    <li>
      <p>
        In partnership with Neuron23, QIAGEN will develop and validate a clinical trial assay (test-kit) that will predict how responsive patients with Parkinson's disease will be to an LRRK2 (leucine-rich repeat kinase 2) inhibitor. Subsequently, the companies aim to submit the CDx for FDA&rsquo;s premarket approval. The companies claim this will be the first CDx developed for Parkinson&rsquo;s disease.&nbsp;
      </p>
    </li>
    <li>
      <p>
        In addition, QIAGEN will support the development of Neuron23&rsquo;s pre-clinical stage drug candidate and both companies have the option to co-develop other CDx.
      </p>
    </li>
    <li>
      <p>
        QIAGEN is a pioneer in developing CDx with pharmaceutical and biotechnology companies to detect various gene mutations to treat diseases such as cancer. It currently has ten FDA approved polymerase chain reaction (PCR) based CDx.&nbsp;&nbsp;&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/neuron23-and-qiagen-announce-collaboration-to-develop-the-first-next-generation-sequencing-companion-diagnostic-for-novel-parkinsons-disease-drug-301623586.html">
      PR Newswire
    </a>
    &nbsp;
  </p>
  <p>
    <a href="https://www.businesswire.com/news/home/20220914005539/en/QIAGEN-and-Neuron23-Partner-to-Develop-Next-Generation-Sequencing-Companion-Diagnostic-for-Novel-Parkinson%E2%80%99s-Disease-Drug">
      Business Wire
    </a>
    &nbsp;
  </p>
  <p>
  </p>
</div>


AI Drug Discovery

Neuron23 partners with QIAGEN to develop companion diagnostic for novel Parkinson's disease drug

Leveraging personal data for custom-fit diagnosis and treatment

All Updates

Neuron23 partners with QIAGEN to develop companion diagnostic for novel Parkinson's disease drug

Neuron23 partners with QIAGEN to develop companion diagnostic for novel Parkinson's disease drug

Neuron23 raises USD 100 million in Series C

Neuron23 raises USD 100 million in Series C